Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have garnered a consensus rating of “Buy” from eight analysts who are covering the company, as reported by Marketbeat Ratings. All eight of these research analysts have rated the stock with a buy rating, suggesting optimism regarding its future performance. The average one-year price target for TSHA shares set by these brokers stands at $6.63.

Recently, several analysts have shared their insights on TSHA shares. For instance, Canaccord Genuity Group raised their target price from $6.00 to $8.00 for Taysha Gene Therapies, maintaining their “buy” rating in a report published on November 15th. Needham & Company LLC also reiterated a “buy” rating and set a price target of $6.00 for the stock in a report released on February 27th. Additionally, Chardan Capital reaffirmed a “buy” rating while establishing a target price of $7.00 in a report issued on February 26th.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors have recently adjusted their positions in Taysha Gene Therapies. Squarepoint Ops LLC increased its stake in the firm by 105.4% in the fourth quarter, now holding 211,842 shares valued at $366,000 after acquiring an additional 108,719 shares. Rafferty Asset Management LLC took a new position in Taysha Gene Therapies during the fourth quarter, investing approximately $436,000. ProShare Advisors LLC raised their stake by 32.3% in the same period, holding 59,076 shares worth about $102,000 after buying an additional 14,418 shares. Furthermore, Octagon Capital Advisors LP boosted its shares by 128.6% in the fourth quarter, now owning 10,450,000 shares valued at $18,078,000 after a purchase of 5,877,778 shares. Lastly, Millennium Management LLC acquired a new stake worth around $262,000. Overall, institutional investors and hedge funds own 77.70% of the stock.

Taysha Gene Therapies Stock Performance

The TSHA stock opened at $1.72 on a recent Tuesday. The company maintains a debt-to-equity ratio of 0.48, with both a quick ratio and current ratio of 5.51. Taysha Gene Therapies has a market capitalization of $352.60 million, a price-to-earnings ratio of 2.73, and a beta of 0.91. Over the past year, the stock has reached a low of $1.19 and a high of $4.32. Its 50-day moving average price is noted at $1.66, while the 200-day moving average price is $1.94.

Taysha Gene Therapies last reported quarterly earnings on February 26th, where it showed earnings per share (EPS) of ($0.07), surpassing analysts’ expectations of ($0.08) by $0.01. The company posted revenue of $2.02 million for the quarter, slightly below the consensus estimate of $2.05 million. The company displayed a negative return on equity of 106.36% and a significant negative net margin of 229.67%. Analysts forecast a projected EPS of -0.35 for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc. specializes in the development and commercialization of adeno-associated virus-based gene therapies aimed at treating monogenic diseases that affect the central nervous system. The company is focused on multiple therapies, including TSHA-120 for giant axonal neuropathy, TSHA-102 for Rett syndrome, and various others targeting CLN7 disease, tauopathies, and other genetic disorders.

Taysha, Gene, Therapies, Stock, Target